Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing

Abstract

Embodiments of the present disclosure concerns methods and compositions related to treatment using a CRISPR/Cas9/targeting antibody/gene targeting small guide RNA (sgRNA) fusion protein/ribonucleotide complex. The targeting of a polynucleotide of interest, such as a gene, may be effective to eradicate tumors in mammals. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are contemplated. In some embodiments, the targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR-based gene modification in vivo obviating the need for adoptive cell therapy. In some cases, substitutions of the CD25 targeting antibody is replaced with another antibody to recognize other cell surface antigens. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are described.

Dependencies are inferred from the claim text.